Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | CCR6 | P51684 | 2/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.31 |
| ▸ | EDNRB | P24530 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5815583 | 0.81 | TRPV1 (0.40) | TNNI3KTRPV1SCN9ACCR6LIPE | |
| SCHEMBL6478217 | 0.81 | TNNI3K (0.37) | TNNI3KTRPV1SCN9ACCR6LIPE | |
| SCHEMBL6478202 | 0.78 | KDM4E (0.40) | TNNI3KTRPV1 | |
| SCHEMBL6473478 | 0.77 | TRPV1 (0.38) | TNNI3KTRPV1SCN9ACCR6LIPE | |
| SCHEMBL5798389 | 0.74 | TRPV1 (0.45) | TRPV1 | |
| SCHEMBL5797694 | 0.72 | CCR6 (0.36) | TNNI3KTRPV1SCN9ACCR6 | |
| SCHEMBL6032969 | 0.71 | TNNI3K (0.35) | TNNI3KTRPV1EDNRBEDNRA | |
| SCHEMBL5801629 | 0.69 | TRPV1 (0.47) | TRPV1 | |
| SCHEMBL5799338 | 0.67 | TRPV1 (0.46) | TRPV1 | |
| SCHEMBL5800142 | 0.67 | TRPV1 (0.50) | TNNI3KTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | HOLLINGWORTH GREGORY J (GB) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | OPRL1, OPRK1, CNR1 | TNNI3K 2340/4885TRPV1 11/4885SCN9A 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.